SAN DIEGO — Sequencing behemoth Illumina on Thursday won its case against the Federal Trade Commission in its bid to hold onto Grail, a Bay Area early cancer detection company that the genomics giant acquired for $8 billion last year.
An administrative law judge rejected the FTC’s argument that the San Diego company’s acquisition of Grail would quash competition in the nascent market for multi-cancer early detection, a technology that picks up on a wide range of cancer types by detecting DNA sequence changes, chemical modifications, or other changes through a simple blood draw. It’s a field that analysts estimate could one day grow into a $50 billion market.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
